BIOTIME Research Development from 2010 to 2026

BT3 Stock  EUR 1.35  0.00  0.00%   
BIOTIME's Research Development is decreasing over the years with slightly volatile fluctuation. Overall, Research Development is expected to go to about 16.7 M this year. During the period from 2010 to 2026 BIOTIME Research Development annual values regression line had geometric mean of  23,125,182 and mean square error of 34.2 T. View All Fundamentals
 
Research Development  
First Reported
2019-03-31
Previous Quarter
3.1 M
Current Value
3.3 M
Quarterly Volatility
4.1 M
 
Covid
 
Interest Hikes
Check BIOTIME financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BIOTIME's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 2.1 M or Interest Expense of 0.0, as well as many indicators such as . BIOTIME financial statements analysis is a perfect complement when working with BIOTIME Valuation or Volatility modules.
  
This module can also supplement various BIOTIME Technical models . Check out the analysis of BIOTIME Correlation against competitors.
Analyzing BIOTIME's Research Development over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Research Development has evolved provides context for assessing BIOTIME's current valuation and future prospects.

Latest BIOTIME's Research Development Growth Pattern

Below is the plot of the Research Development of BIOTIME over the last few years. It is BIOTIME's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BIOTIME's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

BIOTIME Research Development Regression Statistics

Arithmetic Mean25,408,769
Geometric Mean23,125,182
Coefficient Of Variation41.65
Mean Deviation9,810,100
Median24,024,000
Standard Deviation10,582,611
Sample Variance112T
Range24.9M
R-Value(0.84)
Mean Square Error34.2T
R-Squared0.71
Significance0.00002
Slope(1,770,219)
Total Sum of Squares1791.9T

BIOTIME Research Development History

202616.7 M
202511.2 M
202412.5 M
202315.7 M
202214 M
202133.9 M
202012.3 M

About BIOTIME Financial Statements

BIOTIME stakeholders use historical fundamental indicators, such as BIOTIME's Research Development, to determine how well the company is positioned to perform in the future. Although BIOTIME investors may analyze each financial statement separately, they are all interrelated. For example, changes in BIOTIME's assets and liabilities are reflected in the revenues and expenses on BIOTIME's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BIOTIME. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development11.2 M16.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in BIOTIME Stock

BIOTIME financial ratios help investors to determine whether BIOTIME Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BIOTIME with respect to the benefits of owning BIOTIME security.